The 5th edition of the World Health Organization Classification of mature lymphoid and stromal tumors – an overview and update

References

• Swerdlow SH, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues: Revised 4th edition. 2017.
   Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. World health organization classification of tumours of haematopoietic and lymphoid tissues. 2008.
   Google Scholar
• Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-Line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–1344. doi:10.1056/NEJMoa1614598
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018;36(23):2395–2404. doi:10.1200/JCO.2017.76.8960
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934–947. doi:10.1056/NEJMoa1805104
   PubMed Web of Science ®Google Scholar
• Rimsza LM, Li H, Braziel RM, et al. Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica. 2018;103(4):e151–e153. doi:10.3324/haematol.2017.175059
   PubMed Web of Science ®Google Scholar
• Bachy E, Seymour JF, Feugier P, et al. Sustained progression-Free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-Term results of the PRIMA study. J Clin Oncol. 2019;37(31):2815–2824. doi:10.1200/JCO.19.01073
   PubMed Web of Science ®Google Scholar
• Schmidt J, Gong S, Marafioti T, et al. Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood. 2016;128(8):1101–1111. doi:10.1182/blood-2016-03-703819
   PubMed Web of Science ®Google Scholar
• El Behery R, Laurini JA, Weisenburger DD, et al. Follicular large cleaved cell (centrocytic) lymphoma: an unrecognized variant of follicular lymphoma. Hum Pathol. 2018;72:180–190. doi:10.1016/j.humpath.2017.11.002
   PubMed Web of Science ®Google Scholar
• Laurent C, Adélaïde J, Guille A, et al. High-grade follicular lymphomas exhibit clinicopathologic, cytogenetic, and molecular diversity extending beyond grades 3A and 3B. Am J Surg Pathol. 2021;45(10):1324–1336. doi:10.1097/PAS.0000000000001726
   PubMed Web of Science ®Google Scholar
• El Hussein S, Khoury JD, Medeiros LJ. B-prolymphocytic leukemia: is it time to retire this entity? Ann Diagn Pathol. 2021;54:151790. doi:10.1016/j.anndiagpath.2021.151790
   PubMed Web of Science ®Google Scholar
• Siebert R, Schuh A, Ott G, et al. Response to the comments from the groupe francophone de cytogénétique hématologique (GFCH) on the 5th edition of the world health organization classification of haematolymphoid tumors. Leukemia. 2023;37(5):1170–1172. doi:10.1038/s41375-023-01872-6
   PubMedGoogle Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-1545
   PubMed Web of Science ®Google Scholar
• Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285–1295. doi:10.1200/JCO.18.02403
   PubMed Web of Science ®Google Scholar
• Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123(8):1214–1217. doi:10.1182/blood-2013-11-536433
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690. doi:10.1038/s41591-018-0016-8
   PubMed Web of Science ®Google Scholar
• Wright GW, Da Huang W, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551–568.e14. doi:10.1016/j.ccell.2020.03.015
   PubMed Web of Science ®Google Scholar
• Zamò A, Gerhard-Hartmann E, Ott G, et al. Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series. Virchows Arch. 2022;481(6):935–943. doi:10.1007/s00428-022-03420-6
   PubMed Web of Science ®Google Scholar
• Runge HFP, Lacy S, Barrans S, et al. Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL). Br J Haematol. 2021;192(1):216–220. doi:10.1111/bjh.17132
   PubMed Web of Science ®Google Scholar
• King RL, Goodlad JR, Calaminici M, et al. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. Virchows Arch. 2020;476(5):647–665. doi:10.1007/s00428-019-02698-3
   PubMed Web of Science ®Google Scholar
• Bonzheim I, Sander P, Salmerón-Villalobos J, et al. The molecular hallmarks of primary and secondary vitreoretinal lymphoma. Blood Adv. 2022;6:1598–1607.
   PubMed Web of Science ®Google Scholar
• Salaverria I, Philipp C, Oschlies I, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood. 2011;118(1):139–147. doi:10.1182/blood-2011-01-330795
   PubMed Web of Science ®Google Scholar
• Salaverria I, Martin-Guerrero I, Wagener R, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling burkitt lymphoma. Blood. 2014;123(8):1187–1198. doi:10.1182/blood-2013-06-507996
   PubMed Web of Science ®Google Scholar
• Gonzalez-Farre B, Ramis-Zaldivar JE, Salmeron-Villalobos J, et al. Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to burkitt lymphoma. Haematologica. 2019;104(9):1822–1829. doi:10.3324/haematol.2018.207928
   PubMed Web of Science ®Google Scholar
• Horn H, Kalmbach S, Wagener R, et al. A diagnostic approach to the identification of burkitt-like lymphoma with 11q aberration in aggressive B-cell lymphomas. Am J Surg Pathol. 2021;45(3):356–364. doi:10.1097/PAS.0000000000001613
   PubMed Web of Science ®Google Scholar
• Wagener R, Seufert J, Raimondi F, et al. The mutational landscape of burkitt-like lymphoma with 11q aberration is distinct from that of burkitt lymphoma. Blood. 2019;133(9):962–966. doi:10.1182/blood-2018-07-864025
   PubMed Web of Science ®Google Scholar
• Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev. 2017;31(2):37–42. doi:10.1016/j.blre.2016.09.004
   PubMed Web of Science ®Google Scholar
• Alduaij W, Collinge B, Ben-Neriah S, et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. 2018;141(20):2493–2507. doi:10.1182/blood-2017-12-820605
   Google Scholar
• Ennishi D, Jiang A, Boyle M, et al. Double-Hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(3):190–201. doi:10.1200/JCO.18.01583
   PubMed Web of Science ®Google Scholar
• Sha C, Barrans S, Cucco F, et al. Molecular high-grade B-cell lymphoma: defining a Poor-Risk group that requires different approaches to therapy. J Clin Oncol. 2019;37(3):202–212. doi:10.1200/JCO.18.01314
   PubMed Web of Science ®Google Scholar
• Hilton LK, Tang J, Ben-Neriah S, et al. The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Blood. 2019;134(18):1528–1532. doi:10.1182/blood.2019002600
   PubMed Web of Science ®Google Scholar
• Alexanian S, Said J, Lones M, et al. KSHV/HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states. Am J Surg Pathol. 2013;37(2):241–249. doi:10.1097/PAS.0b013e318267fabc
   PubMed Web of Science ®Google Scholar
• Kaji D, Ota Y, Sato Y, et al. Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis. Blood Adv. 2020;4(18):4442–4450. doi:10.1182/bloodadvances.2020002293
   PubMed Web of Science ®Google Scholar
• Mendeville M, Roemer MGM, van den Hout MFCM, et al. Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma. Blood. 2019;133(4):377–380. doi:10.1182/blood-2017-12-822171
   PubMed Web of Science ®Google Scholar
• Wienand K, Chapuy B, Stewart C, et al. Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv. 2019;3(23):4065–4080. doi:10.1182/bloodadvances.2019001012
   PubMed Web of Science ®Google Scholar
• Weniger MA, Küppers R. Molecular biology of Hodgkin lymphoma. Leukemia. 2021;35(4):968–981. doi:10.1038/s41375-021-01204-6
   PubMed Web of Science ®Google Scholar
• Dojcinov SD, Venkataraman G, Raffeld M, et al. EBV positive mucocutaneous ulcer–a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol. 2010;34(3):405–417. doi:10.1097/PAS.0b013e3181cf8622
   PubMed Web of Science ®Google Scholar
• Dojcinov SD, Venkataraman G, Pittaluga S, et al. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood. 2011;117(18):4726–4735. doi:10.1182/blood-2010-12-323238
   PubMed Web of Science ®Google Scholar
• Nicolae A, Pittaluga S, Venkataraman G, et al. Peripheral T-cell lymphomas of follicular T-helper cell derivation with hodgkin/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist. Am J Surg Pathol. 2013;37(6):816–826. doi:10.1097/PAS.0b013e3182785610
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Copie-Bergman C, Damotte D, et al. Gray-zone lymphoma between cHL and large B-cell lymphoma: a histopathologic series from the LYSA. Am J Surg Pathol. 2019;43(3):341–351. doi:10.1097/PAS.0000000000001198
   PubMed Web of Science ®Google Scholar
• Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin’s lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29(11):1411–1421. doi:10.1097/01.pas.0000180856.74572.73
   PubMed Web of Science ®Google Scholar
• Eberle FC, Rodriguez-Canales J, Wei L, et al. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical hodgkin’s lymphoma and primary mediastinal large B-cell lymphoma. Haematologica. 2011;96(4):558–566. doi:10.3324/haematol.2010.033167
   PubMed Web of Science ®Google Scholar
• Pittaluga S, Nicolae A, Wright GW, et al. Gene expression profiling of mediastinal gray zone lymphoma and its relationship to primary mediastinal B-cell lymphoma and classical hodgkin lymphoma. Blood Cancer Discov. 2020;1(2):155–161. doi:10.1158/2643-3230.BCD-20-0009
   PubMedGoogle Scholar
• Sarkozy C, Hung SS, Chavez EA, et al. Mutational landscape of gray zone lymphoma. Blood. 2021;137(13):1765–1776. doi:10.1182/blood.2020007507
   PubMed Web of Science ®Google Scholar
• Campo E, Jaffe ES. Taking gray zone lymphomas out of the shadows. Blood. 2021;137(13):1703–1704. doi:10.1182/blood.2020009265
   PubMed Web of Science ®Google Scholar
• Nicolae A, Pittaluga S, Abdullah S, et al. EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood. 2015;126(7):863–872. doi:10.1182/blood-2015-02-630632
   PubMed Web of Science ®Google Scholar
• Hartmann S, Döring C, Vucic E, et al. Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. Br J Haematol. 2015;169(3):415–422. doi:10.1111/bjh.13310
   PubMed Web of Science ®Google Scholar
• Hartmann S, Eichenauer DA. Nodular lymphocyte predominant hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma. Pathology. 2020;52(1):142–153. doi:10.1016/j.pathol.2019.10.003
   PubMed Web of Science ®Google Scholar
• Fan Z, Natkunam Y, Bair E, et al. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003;27(10):1346–1356. doi:10.1097/00000478-200310000-00007
   PubMed Web of Science ®Google Scholar
• Randen U, Trøen G, Tierens A, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014;99(3):497–504. doi:10.3324/haematol.2013.091702
   PubMed Web of Science ®Google Scholar
• Małecka A, Trøen G, Tierens A, et al. Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease. Br J Haematol. 2018;183(5):838–842. doi:10.1111/bjh.15063
   PubMed Web of Science ®Google Scholar
• Małecka A, Delabie J, Østlie I, et al. Cold agglutinin-associated B-cell lymphoproliferative disease shows highly recurrent gains of chromosome 3 and 12 or 18. Blood Adv. 2020;4(6):993–996. doi:10.1182/bloodadvances.2020001608
   PubMed Web of Science ®Google Scholar
• Bridoux F, Leung N, Hutchison CA, et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015;87(4):698–711. doi:10.1038/ki.2014.408
   PubMed Web of Science ®Google Scholar
• Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7(2):231–239. doi:10.2215/CJN.08640811
   PubMed Web of Science ®Google Scholar
• Joly F, Cohen C, Javaugue V, et al. Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. Blood. 2019;133(6):576–587. doi:10.1182/blood-2018-09-872028
   PubMed Web of Science ®Google Scholar
• Bhargava P, Rushin JM, Rusnock EJ, et al. Pulmonary light chain deposition disease: report of five cases and review of the literature. Am J Surg Pathol. 2007;31(2):267–276. doi:10.1097/01.pas.0000213358.18380.d2
   PubMed Web of Science ®Google Scholar
• Colombat M, Stern M, Groussard O, et al. Pulmonary cystic disorder related to light chain deposition disease. Am J Respir Crit Care Med. 2006;173(7):777–780. doi:10.1164/rccm.200510-1620CR
   PubMed Web of Science ®Google Scholar
• Mohan M, Buros A, Mathur P, et al. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol. 2017;92(8):739–745. doi:10.1002/ajh.24756
   PubMed Web of Science ®Google Scholar
• Vos JM, Gustine J, Rennke HG, et al. Renal disease related to waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016;175(4):623–630. doi:10.1111/bjh.14279
   PubMed Web of Science ®Google Scholar
• Higgins L, Nasr SH, Said SM, et al. Kidney involvement of patients with waldenström macroglobulinemia and other IgM-producing B cell lymphoproliferative disorders. Clin J Am Soc Nephrol. 2018;13(7):1037–1046. doi:10.2215/CJN.13041117
   PubMed Web of Science ®Google Scholar
• Tsai H-T, Caporaso NE, Kyle RA, et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood. 2009;114(24):4928–4932. doi:10.1182/blood-2009-08-237651
   PubMed Web of Science ®Google Scholar
• Stratta P, Gravellone L, Cena T, et al. Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: a single center experience. Crit Rev Oncol Hematol. 2011;79(1):31–42. doi:10.1016/j.critrevonc.2010.05.001
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48. doi:10.1016/S1470-2045(14)70442-5
   PubMed Web of Science ®Google Scholar
• Fernández de Larrea C, Kyle R, Rosiñol L, et al. Primary plasma cell leukemia: consensus definition by the international myeloma working group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11(12):192. doi:10.1038/s41408-021-00587-0
   PubMed Web of Science ®Google Scholar
• Rongioletti F, Romanelli P, Rebora A. Cutaneous mucinous angiomatosis as a presenting sign of bone plasmacytoma: a new case of (A)ESOP syndrome. J Am Acad Dermatol. 2006;55(5):909–910. doi:10.1016/j.jaad.2006.04.072
   PubMed Web of Science ®Google Scholar
• Sakemi H, Okada H. An autopsy case of Crow-Fukase syndrome which developed 18 years after the first manifestation of plasmacytoma. Intern Med. 1992;31(1):50–54. doi:10.2169/internalmedicine.31.50
   PubMed Web of Science ®Google Scholar
• Bousfiha A, Moundir A, Tangye SG, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022;42(7):1508–1520. doi:10.1007/s10875-022-01352-z
   PubMed Web of Science ®Google Scholar
• Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee. J Clin Immunol. 2022;42(7):1473–1507. doi:10.1007/s10875-022-01289-3
   PubMed Web of Science ®Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-022-01613-1
   PubMed Web of Science ®Google Scholar
• Menter T, Juskevicius D, Alikian M, et al. Mutational landscape of B-cell post-transplant lymphoproliferative disorders. Br J Haematol. 2017;178(1):48–56. doi:10.1111/bjh.14633
   PubMed Web of Science ®Google Scholar
• Ye X, Maglione PJ, Wehr C, et al. Genomic characterization of lymphomas in patients with inborn errors of immunity. Blood Adv. 2022;6(18):5403–5414. doi:10.1182/bloodadvances.2021006654
   PubMed Web of Science ®Google Scholar
• Cabanié C, Ammari S, Hans S, et al. Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: a case-control study. Eur J Cancer. 2021;156:46–59. doi:10.1016/j.ejca.2021.07.015
   PubMed Web of Science ®Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Steinhilber J, Mederake M, Bonzheim I, et al. The pathological features of angioimmunoblastic T-cell lymphomas with IDH2R172 mutations. Mod Pathol. 2019;32(8):1123–1134. doi:10.1038/s41379-019-0254-4
   PubMed Web of Science ®Google Scholar
• Attygalle AD, Chuang S-S, Diss TC, et al. Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology. 2007;50(4):498–508. doi:10.1111/j.1365-2559.2007.02632.x
   PubMed Web of Science ®Google Scholar
• Tokunaga T, Shimada K, Yamamoto K, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood. 2012;119(12):2837–2843. doi:10.1182/blood-2011-08-374371
   PubMed Web of Science ®Google Scholar
• Leval L D, Parrens M, Le Bras F, et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica. 2015;100(9):e361-4–e364. doi:10.3324/haematol.2015.126300
   PubMed Web of Science ®Google Scholar
• Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171–175. doi:10.1038/ng.2872
   PubMed Web of Science ®Google Scholar
• Schwartz FH, Cai Q, Fellmann E, et al. TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma. J Pathol. 2017;242(2):129–133. doi:10.1002/path.4898
   PubMed Web of Science ®Google Scholar
• Wang C, McKeithan TW, Gong Q, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015;126(15):1741–1752. doi:10.1182/blood-2015-05-644591
   PubMed Web of Science ®Google Scholar
• Yao W-Q, Wu F, Zhang W, et al. Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell. J Pathol. 2020;250(3):346–357. doi:10.1002/path.5376
   PubMed Web of Science ®Google Scholar
• Attygalle AD, Dobson R, Chak PK, et al. Parallel evolution of two distinct lymphoid proliferations in clonal haematopoiesis. Histopathology. 2022;80(5):847–858. doi:10.1111/his.14619
   PubMed Web of Science ®Google Scholar
• Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473–1480. doi:10.1182/blood-2014-04-571091
   PubMed Web of Science ®Google Scholar
• Pedersen MB, Hamilton-Dutoit SJ, Bendix K, et al. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood. 2017;130(4):554–557. doi:10.1182/blood-2016-12-755496
   PubMed Web of Science ®Google Scholar
• Hapgood G, Ben-Neriah S, Mottok A, et al. Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. Br J Haematol. 2019;186(3):e28–e31. doi:10.1111/bjh.15860
   PubMed Web of Science ®Google Scholar
• Qiu L, Tang G, Li S, et al. DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma. Haematologica. 2023;108(6):1604–1615. doi:10.3324/haematol.2022.281222
   PubMed Web of Science ®Google Scholar
• Boi M, Rinaldi A, Kwee I, et al. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood. 2013;122(15):2683–2693. doi:10.1182/blood-2013-04-497933
   PubMed Web of Science ®Google Scholar
• Liang H-C, Costanza M, Prutsch N, et al. Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma. Nat Commun. 2021;12(1):5577. doi:10.1038/s41467-021-25379-9
   PubMed Web of Science ®Google Scholar
• King RL, Dao LN, McPhail ED, et al. Morphologic features of ALK-negative anaplastic large cell lymphomas with DUSP22 rearrangements. Am J Surg Pathol. 2016;40(1):36–43. doi:10.1097/PAS.0000000000000500
   PubMed Web of Science ®Google Scholar
• Feldman AL, Oishi N, Ketterling RP, et al. Immunohistochemical approach to genetic subtyping of anaplastic large cell lymphoma. Am J Surg Pathol. 2022;46(11):1490–1499. doi:10.1097/PAS.0000000000001941
   PubMed Web of Science ®Google Scholar
• Scarfò I, Pellegrino E, Mereu E, et al. Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood. 2016;127(2):221–232. doi:10.1182/blood-2014-12-614503
   PubMed Web of Science ®Google Scholar
• Fitzpatrick MJ, Massoth LR, Marcus C, et al. JAK2 rearrangements are a recurrent alteration in CD30+ systemic T-cell lymphomas with anaplastic morphology. Am J Surg Pathol. 2021;45(7):895–904. doi:10.1097/PAS.0000000000001708
   PubMed Web of Science ®Google Scholar
• Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915–2923. doi:10.1182/blood-2013-11-536359
   PubMed Web of Science ®Google Scholar
• Mitteldorf C, Stadler R, Sander CA, et al. Folliculotropic mycosis fungoides. J Dtsch Dermatol Ges. 2018;16(5):543–557. doi:10.1111/ddg.13514
   PubMed Web of Science ®Google Scholar
• Kempf W, Petrella T, Willemze R, et al. Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC cutaneous lymphoma group workshop. Br J Dermatol. 2022;186(5):887–897. doi:10.1111/bjd.20973
   PubMed Web of Science ®Google Scholar
• Kempf W, Kerl K, Mitteldorf C. Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018;37(1):24–29. doi:10.12788/j.sder.2018.001
   PubMed Web of Science ®Google Scholar
• Csikesz CR, Knudson RA, Greipp PT, et al. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders with biallelic rearrangements of DUSP22. J Invest Dermatol. 2013;133(6):1680–1682. doi:10.1038/jid.2013.22
   PubMed Web of Science ®Google Scholar
• Vasmatzis G, Johnson SH, Knudson RA, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012;120(11):2280–2289. doi:10.1182/blood-2012-03-419937
   PubMed Web of Science ®Google Scholar
• Velusamy T, Kiel MJ, Sahasrabuddhe AA, et al. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood. 2014;124(25):3768–3771. doi:10.1182/blood-2014-07-588434
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Polprasert C, Takeuchi Y, Kakiuchi N, et al. Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma. Blood Adv. 2019;3(4):588–595. doi:10.1182/bloodadvances.2018028340
   PubMed Web of Science ®Google Scholar
• Koh J, Jang I, Mun S, et al. Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations. Blood Adv. 2021;5(20):3919–3930. doi:10.1182/bloodadvances.2021004562
   PubMed Web of Science ®Google Scholar
• Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–1714. doi:10.1182/blood-2018-11-881268
   PubMed Web of Science ®Google Scholar
• Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas-An update 2021. Hematol Oncol. 2021;39 Suppl 1:46–51. doi:10.1002/hon.2850
   PubMed Web of Science ®Google Scholar
• Sanikommu SR, Clemente MJ, Chomczynski P, et al. Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leuk Lymphoma. 2018;59(2):416–422. doi:10.1080/10428194.2017.1339880
   PubMed Web of Science ®Google Scholar
• Muñoz-García N, Jara-Acevedo M, Caldas C, et al. STAT3 and STAT5B mutations in T/NK-cell chronic lymphoproliferative disorders of large granular lymphocytes (LGL): association with disease features. Cancers (Basel). 2020;12(12):3508. doi:10.3390/cancers12123508
   PubMed Web of Science ®Google Scholar
• Kawa-Ha K, Ishihara S, Ninomiya T, et al. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest. 1989;84(1):51–55. doi:10.1172/JCI114168
   PubMed Web of Science ®Google Scholar
• Hart DN, Baker BW, Inglis MJ, et al. Epstein-Barr viral DNA in acute large granular lymphocyte (natural killer) leukemic cells. Blood. 1992;79(8):2116–2123. doi:10.1182/blood.V79.8.2116.2116
   PubMed Web of Science ®Google Scholar
• Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997;89(12):4501–4513. doi:10.1182/blood.V89.12.4501
   PubMed Web of Science ®Google Scholar
• Iqbal J, Weisenburger DD, Chowdhury A, et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel Aurora kinase a inhibitor in vitro. Leukemia. 2011;25(2):348–358. doi:10.1038/leu.2010.255
   PubMed Web of Science ®Google Scholar
• Ishida F, Ko YH, Kim WS, et al. Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. Cancer Sci. 2012;103(6):1079–1083. doi:10.1111/j.1349-7006.2012.02251.x
   PubMed Web of Science ®Google Scholar
• Gao J, Behdad A, Ji P, et al. EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution. Mod Pathol. 2017;30(8):1100–1115. doi:10.1038/modpathol.2017.37
   PubMed Web of Science ®Google Scholar
• Suzuki R, Suzumiya J, Nakamura S, et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia. 2004;18(4):763–770. doi:10.1038/sj.leu.2403262
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Yokoyama M, Ishizawa S, et al. Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood. 2010;116(25):5631–5637. doi:10.1182/blood-2010-06-290650
   PubMed Web of Science ®Google Scholar
• Mansoor A, Pittaluga S, Beck PL, et al. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood. 2011;117(5):1447–1452. doi:10.1182/blood-2010-08-302737
   PubMed Web of Science ®Google Scholar
• Xiao W, Gupta GK, Yao J, et al. Recurrent somatic JAK3 mutations in NK-cell enteropathy. Blood. 2019;134(12):986–991. doi:10.1182/blood.2019001443
   PubMedGoogle Scholar
• Xia D, Morgan EA, Berger D, et al. NK-cell enteropathy and similar indolent lymphoproliferative disorders: a case series with literature review. Am J Clin Pathol. 2019;151:75–85.
   PubMed Web of Science ®Google Scholar
• Krishnan R, Ring K, Williams E, et al. An enteropathy-like indolent NK-cell proliferation presenting in the female genital tract. Am J Surg Pathol. 2020;44(4):561–565. doi:10.1097/PAS.0000000000001387
   PubMed Web of Science ®Google Scholar
• Dargent J-L, Tinton N, Trimech M, et al. Lymph node involvement by enteropathy-like indolent NK-cell proliferation. Virchows Arch. 2021;478(6):1197–1202. doi:10.1007/s00428-020-02892-8
   PubMed Web of Science ®Google Scholar
• Yi H, Li A, Ouyang B, et al. Clinicopathological and molecular features of indolent natural killer-cell lymphoproliferative disorder of the gastrointestinal tract. Histopathology. 2023;82(4):567–575. doi:10.1111/his.14850
   PubMed Web of Science ®Google Scholar
• Xiong J, Cui B-W, Wang N, et al. Genomic and transcriptomic characterization of natural killer T cell lymphoma. Cancer Cell. 2020;37(3):403–419.e6. doi:10.1016/j.ccell.2020.02.005
   PubMed Web of Science ®Google Scholar
• Dong G, Liu X, Wang L, et al. Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma. Leukemia. 2022;36(8):2064–2075. doi:10.1038/s41375-022-01623-z
   PubMed Web of Science ®Google Scholar
• Jeon YK, Kim J-H, Sung J-Y, et al. Epstein-Barr virus-positive nodal T/NK-cell lymphoma: an analysis of 15 cases with distinct clinicopathological features. Hum Pathol. 2015;46(7):981–990. doi:10.1016/j.humpath.2015.03.002
   PubMed Web of Science ®Google Scholar
• Jung KS, Cho S-H, Kim SJ, et al. Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma. Int J Hematol. 2016;104(5):591–595. doi:10.1007/s12185-016-2068-1
   PubMed Web of Science ®Google Scholar
• Ng S-B, Chung T-H, Kato S, et al. Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes. Haematologica. 2018;103(2):278–287. doi:10.3324/haematol.2017.180430
   PubMed Web of Science ®Google Scholar
• Yamashita D, Shimada K, Takata K, et al. Reappraisal of nodal Epstein-Barr virus-negative cytotoxic T-cell lymphoma: identification of indolent CD5+ diseases. Cancer Sci. 2018;109(8):2599–2610. doi:10.1111/cas.13652
   PubMed Web of Science ®Google Scholar
• Wai CMM, Chen S, Phyu T, et al. Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS. Haematologica. 2022;107(8):1864–1879. doi:10.3324/haematol.2021.280003
   PubMed Web of Science ®Google Scholar
• Cohen JI, Manoli I, Dowdell K, et al. Hydroa vacciniforme-like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in whites. Blood. 2019;133(26):2753–2764. doi:10.1182/blood.2018893750
   PubMed Web of Science ®Google Scholar
• Bofill M, Akbar AN, Amlot PL. Follicular dendritic cells share a membrane-bound protein with fibroblasts. J. Pathol. 2000;191(2):217–226. doi:10.1002/(SICI)1096-9896(200006)191:2<217::AID-PATH586>3.0.CO;2-6
   PubMed Web of Science ®Google Scholar
• van Nierop K, Groot C D Human follicular dendritic cells: function, origin and development. Semin Immunol. 2002;14(4):251–257. doi:10.1016/s1044-5323(02)00057-x
   PubMed Web of Science ®Google Scholar
• Jarjour M, Jorquera A, Mondor I, et al. Fate mapping reveals origin and dynamics of lymph node follicular dendritic cells. J Exp Med. 2014;211(6):1109–1122. doi:10.1084/jem.20132409
   PubMed Web of Science ®Google Scholar